Clinicopathological findings, treatment, and outcome in 60 cats with gastrointestinal eosinophilic sclerosing fibroplasia
Journal of Veterinary Internal Medicine · 2024-03-01 · 38 (2) · 1005-1012
DOI: 10.1111/jvim.16992 ↗At a glance
Journal article in Journal of Veterinary Internal Medicine, published online on 2024-03-01. Written by Petra Černá and 9 co-authors. Institution: Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado, USA. Major MEDLINE topics: Eosinophilia, Enteritis, Gastritis, Cat Diseases. Cited 23 times so far (Crossref); 20 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Background
Gastrointestinal eosinophilic sclerosing fibroplasia (GESF) in cats presents as mass(es) associated with the gastrointestinal tract, mesentery, and abdominal lymph nodes. Hypothesis/Objectives To report the clinicopathological findings, treatment, and outcome of cats with GESF. Animals Sixty client-owned cats diagnosed with GESF.
Methods
Retrospective review of medical records of cats with histopathologically confirmed GESF.
Results
The median age was 5.4 years (interquartile range [IQR], 3.3-8.9.); 30% were Domestic Shorthairs and 12% were Domestic Longhair cats, with the most prevalent pedigree breeds being Ragdolls (25%), Exotic Shorthair (10%) and Persian (8%) cats. The median duration of clinical signs was 90 days (IQR, 17.5-247.0); the most common clinical signs were weight loss (60%), hyporexia/anorexia (55%), chronic vomiting (37%), lethargy (35%) and chronic diarrhea (27%). Masses were located in the small intestine (32%), stomach (27%), ileocolic junction (15%), colon (10%), lymph node (8%) and mesentery (8%) and 15% of cats had >1 mass. Eosinophilia was present in 50% and hypoalbuminemia in 28% of cats. The mass was removed surgically in 37% of cases. Most cats (98%) were treated with corticosteroids. Survival was not statistically different between cats treated with surgical resection and cats treated with medical therapy alone, 88% of the cats were still alive at the time of writing. Conclusions and Clinical Importance GESF is an important differential diagnosis for abdominal masses in cats, and has a much better prognosis than previously reported.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado, USA.
- Small Animal Clinic, The University of Veterinary Sciences Brno, Brno, Czech Republic.
- North Downs Specialist Referrals, Bletchingley, UK.
- Veterinary Specialists & Emergency Center, Kawaguchi-shi, Saitama, Japan.
- Small Animal Medical Center, Saitama, Japan.
- Veterinary Medical Centre, The University of Tokyo, Tokyo, Japan.
ORCID profiles: Petra Černá, Ko Nakashima, Nicolas Israeliantz
Cite
APA
Černá, P., Lopez-Jimenez, C., Fukushima, K., Nakashima, K., Nakagawa, T., Adam, F., Groth, A., Denning, A., Israeliantz, N., & Gunn-Moore, D. A. (2024). Clinicopathological findings, treatment, and outcome in 60 cats with gastrointestinal eosinophilic sclerosing fibroplasia. Journal of Veterinary Internal Medicine, 38(2), 1005-1012. https://doi.org/10.1111/jvim.16992
Vancouver
Černá P, Lopez-Jimenez C, Fukushima K, Nakashima K, Nakagawa T, Adam F, et al. Clinicopathological findings, treatment, and outcome in 60 cats with gastrointestinal eosinophilic sclerosing fibroplasia. Journal of Veterinary Internal Medicine. 2024;38(2):1005-1012. doi:10.1111/jvim.16992
BibTeX
@article{ern2024,
author = {Černá, Petra and Lopez-Jimenez, Cristobal and Fukushima, Kenjiro and Nakashima, Ko and Nakagawa, Taisuke and Adam, Fiona and Groth, Anna and Denning, Andrew and Israeliantz, Nicolas and Gunn-Moore, Danièlle A},
title = {Clinicopathological findings, treatment, and outcome in 60 cats with gastrointestinal eosinophilic sclerosing fibroplasia},
journal = {Journal of Veterinary Internal Medicine},
year = {2024},
volume = {38},
number = {2},
pages = {1005--1012},
doi = {10.1111/jvim.16992}
}
EUVIMED